COVID-19: a “repurposed” drug soon to enter clinical trials

Radio-Canada, 2021-06-14

“A treatment aimed at reducing and possibly preventing the development of severe lung inflammation related to COVID-19 will soon be the subject of a phase III clinical trial, overseen by the Research Institute of the McGill University Health Centre (RI-MUHC).”

Read the full article